Jun 6 |
Will Intensity Therapeutics (NASDAQ:INTS) Spend Its Cash Wisely?
|
May 15 |
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors
|
May 14 |
Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug
|
Apr 2 |
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
|
Mar 26 |
Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares
|
Mar 14 |
Intensity Therapeutics GAAP EPS of -$1.38
|
Mar 14 |
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update
|
Mar 14 |
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
|
Feb 21 |
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
|
Jan 3 |
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
|